It has been about a month since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 1.7% in that time frame, underperforming the S&P 500. Will the recent negative ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other worst performers on Monday. Corcept Therapeutics dropped for a third ...

H.C. Wainwright analysts on Tuesday maintained their $145 price target and Buy rating for Corcept Therapeutics Incorporated (NASDAQ:CORT), reflecting a significant upside potential from its ...

Find out more about how we test. The KX507MS Pale Moon is the latest 7-string, multiscale electric guitar in Cort’s KX range. This newest version takes its name from the Pale Moon ebony top which is ...

Corcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in patients with amyotrophic lateral sclerosis did not meet the main goal.

Corcept Therapeutics CORT has outperformed the market over the past 5 years by 26.38% on an annualized basis producing an average annual return of 40.21%. Currently, Corcept Therapeutics has a ...

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

A WNBA game isn't just about the basketball; it's a celebration of great athleticism and passionate community support by die-hard fans. The vibe inside a home court is electrifying with ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...